Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (IMSS), Argentina 1, 62790, Xochitepec, Morelos, Mexico; Laboratorio de Farmacología, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana (UAM), Mexico City, Mexico; Doctorado en Ciencias Biológicas y de la Salud, Departamento de Ciencias de la Salud, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana Iztapalapa, Av. San Rafael Atlixco No. 186, Col. Vicentina, Iztapalapa, 09340, Mexico City, Mexico.
Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (IMSS), Argentina 1, 62790, Xochitepec, Morelos, Mexico.
Biomed Pharmacother. 2018 Jul;103:879-888. doi: 10.1016/j.biopha.2018.04.082. Epub 2018 Apr 24.
Due to the high prevalence of psychiatric disorders and the prevalent side effects produced by the antipsychotic drugs available, it is necessary to search for new therapeutic options. Galphimia glauca has been used for many years in Mexican traditional medicine for treating mental diseases. From this plant, some compounds, denominated galphimines, have been discovered and have shown to possess the ability of modifying the frequency of discharge of dopaminergic neurons in the Ventral tegmental area. The objective of the present work was to evaluate the effect produced by the G. glauca extract, a Galphimine rich fraction (GRF), as well as the pure galphimines (G-A, G-B, and G-E) on behavioral models in mice. Products obtained from G. glauca were evaluated in the Haloperidol-induced catalepsy test and in the acute schizophrenia-like symptoms-induced with Ketamine (KET) in mice. Catalepsy was evaluated through the bar test, and schizophrenia-like symptoms, by means of the Open Field Test (OFT), Passive Avoidance Test (PAT), and the Forced Swimming Test (FST). The methanolic extract from G. glauca, GRF, and the pure galphimines were able to interact with the dopaminergic pathway and modify the behavioral response such as to potentiate the cataleptic effect induced with Haloperidol and to inhibit the behavior induced by KET in mice exposed to OFT, and FST. Moreover, the G. glauca extract and GRF were capable of blocking the cognitive decline that was induced with KET in mice (evaluated by PAT). Based on these results, it is possible to assume that part of the effect of G. glauca is due to the interaction of Galphimines with the dopaminergic and glutamatergic systems in vivo. It can be concluded that the products obtained from G. glauca potentiate the cataleptic effect induced with Haloperidol and show a protector effect on some of the symptoms generated by KET in mice (KET is capable of provoking halucinations in humans and psychosis-like behaviour in mice). With this basis, the metanolic extract from G. glauca, and the GRF are capable of blocking positive and cognitive symptoms associated with psychosis induced by KET. In addition, it could be suggested that the galphimines are responsible for the inhibition of the positive symptoms observed.
由于精神障碍的高患病率和现有抗精神病药物普遍存在的副作用,有必要寻找新的治疗选择。Galphimia glauca 多年来一直被用于墨西哥传统医学治疗精神疾病。从这种植物中,发现了一些被称为 galphimines 的化合物,它们具有改变腹侧被盖区多巴胺能神经元放电频率的能力。本工作的目的是评价 G. glauca 提取物、富含 galphimine 的馏分(GRF)以及纯 galphimines(G-A、G-B 和 G-E)对小鼠行为模型的影响。从 G. glauca 中获得的产物在氟哌啶醇诱导的僵住症试验和氯胺酮(KET)诱导的急性精神分裂样症状模型中进行了评价。僵住症通过棒试验进行评估,精神分裂样症状通过旷场试验(OFT)、被动回避试验(PAT)和强迫游泳试验(FST)进行评估。G. glauca 的甲醇提取物、GRF 和纯 galphimines 能够与多巴胺能途径相互作用,改变行为反应,例如增强氟哌啶醇诱导的僵住效应,并抑制暴露于 OFT 和 FST 的小鼠中 KET 诱导的行为。此外,G. glauca 提取物和 GRF 能够阻止 KET 诱导的小鼠认知能力下降(通过 PAT 评估)。基于这些结果,可以假设 G. glauca 的部分作用是由于 Galphimines 与体内多巴胺能和谷氨酸能系统的相互作用。可以得出结论,从 G. glauca 获得的产物增强了氟哌啶醇诱导的僵住效应,并对 KET 在小鼠中引起的一些症状具有保护作用(KET 能够在人类中引起幻觉和类似精神病的行为,在小鼠中引起类似精神病的行为)。在此基础上,G. glauca 的甲醇提取物和 GRF 能够阻断 KET 诱导的与精神病相关的阳性和认知症状。此外,可能表明 galphimines 负责抑制观察到的阳性症状。